Equine allogeneic bone marrow-derived mesenchymal stromal cells elicit antibody responses in vivo

Pezzanite, Lynn M; Fortier, Lisa A; Antczak, Douglas F; Cassano, Jennifer M; Brosnahan, Margaret M; Miller, Donald; Schnabel, Lauren V

doi:10.1186/s13287-015-0053-x

Stem Cell Research & Therapy

Table 3 Microcytotoxicity assay results for the presence of anti-ELA-A2 antibodies in recipient sera

From: Equine allogeneic bone marrow-derived mesenchymal stromal cells elicit antibody responses in vivo

		*Recipient serum dilution*
Recipient horse	Day	Neat	1:2	1:4	1:8	1:16	1:32	1:64	1:128	1:256	1:512	1:1,024	1:2,048
A	0	0	0	0	0	0	0	0	0	0	0	0	0
A	7	0	0	0	0	0	0	0	0	0	0	0	0
A	14	0	0	0	0	0	0	0	0	0	0	0	0
A	21	0	0	0	<10	<10	<10	0	0	0	0	0	0
A	28	20	30	35	30	30	15	10	10	10	10	10	10
A	35	0	0	0	0	0	0	0	0	0	0	0	0
A	Reinjection = 36	0	0	0	0	0	0	0	0	0	0	0	0
A	42	60	<10	0	0	0	0	0	0	0	0	0	0
A	49	90	<10	0	0	0	0	0	0	0	0	0	0
A	56	50	<10	0	0	0	0	0	0	0	0	0	0
B	0	0	0	0	0	0	0	0	0	0	0	0	0
B	7	0	0	0	0	0	0	0	0	0	0	0	0
B	14	80	80	100	90	10	1	15	0	0	0	0	0
B	21	100	100	100	100	80	25	35	20	10	10	5	0
B	28	45	75	90	80	80	45	15	15	15	25	20	25
B	35	80	90	100	50	0	0	0	0	0	0	0	0
B	42	80	100	25	0	0	0	0	0	0	0	0	0
B	49	80	90	0	0	0	0	0	0	0	0	0	0
B	56	80	30	0	0	0	0	0	0	0	0	0	0
C	0	0	0	0	0	0	0	0	0	0	0	0	0
C	7	45	95	80	15	15	1	0	0	0	0	0	0
C	14	100	100	100	100	100	100	100	100	100	100	80	30
C	21	100	100	100	100	100	100	100	100	100	100	85	50
C	28	100	100	100	100	100	100	100	100	100	55	25	15
C	35	100	100	100	100	100	100	100	100	0	0	0	0
C	42	100	100	100	100	100	100	100	50	0	0	0	0
C	49	100	100	100	100	100	100	100	0	0	0	0	0
C	56	100	100	100	100	100	100	0	0	0	0	0	0
D	0	0	0	0	0	0	0	0	0	0	0	0	0
D	7	0	0	0	0	0	0	0	0	0	0	0	0
D	14	0	0	0	0	0	0	0	0	0	0	0	0
D	21	0	0	10	25	25	10	0	0	0	0	0	0
D	28	10	10	10	10	10	10	10	10	10	10	10	10
D	35	0	0	0	0	0	0	0	0	0	0	0	0
D	Reinjection = 36	0	0	0	0	0	0	0	0	0	0	0	0
D	42	0	0	0	0	0	0	0	0	0	0	0	0
D	49	0	0	0	0	0	0	0	0	0	0	0	0
D	56	0	0	0	0	0	0	0	0	0	0	0	0
E	0	0	0	0	0	0	0	0	0	0	0	0	0
E	7	0	0	0	0	0	0	0	0		0	0	0
E	14	65	70	100	50	30	15	15	15	10	10	10	10
E	21	50	60	95	50	15	15	15	15	10	10	10	10
E	28	25	90	35	15	10	10	10	10	10	10	10	10
E	35	0	80	50	0	0	0	0	0	0	0	0	0
E	42	25	25	0	0	0	0	0	0	0	0	0	0
E	49	25	0	0	0	0	0	0	0	0	0	0	0
E	56	25	0	0	0	0	0	0	0	0	0	0	0
F	0	0	0	0	0	0	0	0	0	0	0	0	0
F	7	0	0	0	0	0	0	0	0	0	0	0	0
F	14	25	25	<10	<10	<10	<10	10	15	20	20	20	20
F	21	90	95	95	100	100	90	65	50	25	15	20	10
F	28	40	65	95	90	80	25	20	20	15	10	15	15
F	35	40	80	90	0	0	0	0	0	0	0	0	0
F	42	24	80	25	0	0	0	0	0	0	0	0	0
F	49	40	90	10	0	0	0	0	0	0	0	0	0
F	56	20	80	25	0	0	0	0	0	0	0	0	0
Control (Horse 2)	0	0	0	0	0	0	0	0	0	0	0	0	0
Control (Horse 2)	7	0	0	0	0	0	0	0	0	0	0	0	0
Control (Horse 2)	14	0	0	0	0	0	0	0	0	0	0	0	0
Control (Horse 2)	21	0	0	0	0	0	0	0	0	0	0	0	0
Control (Horse 2)	28	0	0	0	0	0	0	0	0	0	0	0	0
Control (Horse 2)	35	0	0	0	0	0	0	0	0	0	0	0	0
Control (Horse 2)	42	0	0	0	0	0	0	0	0	0	0	0	0
Control (Horse 2)	49	0	0	0	0	0	0	0	0	0	0	0	0
Control (Horse 2)	56	0	0	0	0	0	0	0	0	0	0	0	0
Internal control (A2 – sera)	Days 0 to 28	0	0	0	0	0	0	0	0	0	0	0	0
Internal control (A2 – sera)	Days 35 to 56	0	0	0	0	0	0	0	0	0	0	0	0
Internal control (A2 + sera)	Days 0 to 28	100	100	100	100	100	100	100	100	100	100	100	100
Internal control (A2 + sera)	Days 35 to 56	100	100	100	100	100	100	100	100	100	100	100	100

Data reported as the percentage death of ELA-A2 donor leukocytes. For each time point, the value in italics is the cytotoxic antibody titer (the highest dilution of each antisera that resulted in killing of at least 80% of the donor leukocytes as reported in Figure 2). ELA-A2, equine leukocyte antigen haplotype.

Back to article page

ISSN: 1757-6512

Contact us

Submission enquiries: Access here and click Contact Us
General enquiries: info@biomedcentral.com